Voyager Therapeutics Stock Price Target and Analyst Ratings (NASDAQ:VYGR)

Analyst Price Target for VYGR

i We calculate consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). Our consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. Our consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

^$15.38

▲ +77.45% Upside Potential

This price target is based on 12 analysts offering 12 month price targets for Voyager Therapeutics in the last 3 months. The average price target is $15.38, with a high forecast of $26.00 and a low forecast of $10.00. The average price target represents a 77.45% upside from the last price of $8.67.

Buy

The current consensus among 12 polled investment analysts is to buy stock in Voyager Therapeutics. This rating has held steady since November 2020, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

0 strong buy ratings
6 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

7/30/2019

0 strong buy ratings
6 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

10/28/2019

0 strong buy ratings
4 buy ratings
3 hold ratings
0 sell ratings

Ratings as of

1/26/2020

0 strong buy ratings
5 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

4/25/2020

0 strong buy ratings
6 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

7/24/2020

0 strong buy ratings
6 buy ratings
4 hold ratings
0 sell ratings

Ratings as of

10/22/2020

0 strong buy ratings
5 buy ratings
5 hold ratings
0 sell ratings

Ratings as of

12/21/2020

0 strong buy ratings
6 buy ratings
6 hold ratings
0 sell ratings

Ratings as of

1/20/2021

Latest Recommendations

Show Most Recent Rating from Each Ratings Firm Show All Ratings

Date	Brokerage	Action	Rating	Price Target	Impact on Share Price	Details
1/13/2021	Canaccord Genuity	Reiterated Rating	Buy	$14.00	Low	i
12/23/2020	Cantor Fitzgerald	Downgrade	Overweight ➝ Neutral	$15.00 ➝ $10.00	N/A	i Rating by C. Duncan at Cantor Fitzgerald
12/23/2020	Raymond James	Downgrade	Outperform ➝ Market Perform		N/A	i
11/11/2020	BTIG Research	Lower Price Target		$31.00 ➝ $18.00	High	i
11/11/2020	Oppenheimer	Downgrade	Outperform ➝ Market Perform		High	i
11/10/2020	Wedbush	Lower Price Target	Outperform	$19.00 ➝ $13.00	High	i
11/10/2020	Wells Fargo & Company	Downgrade	Overweight ➝ Equal Weight	$10.00	High	i
11/10/2020	Raymond James	Downgrade	Strong-Buy ➝ Outperform	$28.00 ➝ $17.00	High	i
10/13/2020	Wedbush	Lower Price Target	Hold ➝ Outperform	$24.00 ➝ $19.00	High	i
8/14/2020	Chardan Capital	Reiterated Rating	Hold	$15.00	Medium	i Rating by Gbola Amusa at Chardan Capital
8/12/2020	Wedbush	Reiterated Rating	Buy	$24.00	Low	i
8/4/2020	HC Wainwright	Lower Price Target	Buy	$18.00 ➝ $14.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
5/13/2020	Nomura	Reiterated Rating	Buy	$16.00	Low	i
5/8/2020	Chardan Capital	Reiterated Rating	Hold	$15.00	Low	i Rating by G. Amusa at Chardan Capital
4/15/2020	Morgan Stanley	Lower Price Target	Equal Weight	$14.00 ➝ $13.00	Low	i
3/30/2020	Nomura Securities	Lower Price Target	Buy	$37.00 ➝ $16.00	High	i
3/19/2020	Benchmark	Initiated Coverage	Buy	$18.00	High	i
3/6/2020	Chardan Capital	Reiterated Rating	Hold	$20.00	High	i Rating by Gbola Amusa at Chardan Capital
3/4/2020	HC Wainwright	Lower Price Target	Buy	$26.00 ➝ $18.00	Medium	i
3/4/2020	Morgan Stanley	Lower Price Target	Equal Weight	$15.00 ➝ $14.00	Medium	i Rating by Jeffrey Hung at Morgan Stanley
3/4/2020	Wedbush	Lower Price Target	Outperform	$34.00 ➝ $27.00	High	i Rating by D. Nierengarten at Wedbush
2/5/2020	Oppenheimer	Initiated Coverage	Outperform	$26.00	High	i
11/24/2019	Evercore ISI	Reiterated Rating	Hold	$18.00	Medium	i
11/6/2019	Wedbush	Reiterated Rating	Outperform		Medium	i Rating by D. Nierengarten at Wedbush
11/6/2019	Cowen	Reiterated Rating	Buy		High	i Rating by Phil Nadeau at Cowen Inc
10/15/2019	Cowen	Reiterated Rating	Buy		Low	i
10/11/2019	Morgan Stanley	Lower Price Target	Equal Weight	$28.00 ➝ $26.00	Low	i Rating by Jeffrey Hung at Morgan Stanley
8/13/2019	Nomura Securities	Reiterated Rating	Buy	$37.00	High	i
8/12/2019	HC Wainwright	Reiterated Rating	Buy	$26.00	Medium	i
7/12/2019	Morgan Stanley	Boost Price Target	Equal Weight	$21.00 ➝ $28.00	Medium	i
6/20/2019	Nomura Securities	Boost Price Target	Buy	$26.00 ➝ $37.00	High	i
6/18/2019	Wedbush	Boost Price Target	Outperform	$27.00 ➝ $36.00	High	i
5/6/2019	HC Wainwright	Reiterated Rating	Buy	$22.00	Medium	i Rating by Debjit Chattopadhyay at HC Wainwright
3/5/2019	Cantor Fitzgerald	Initiated Coverage	Overweight	$27.00	High	i Rating by C. Duncan at Cantor Fitzgerald
2/27/2019	Cowen	Reiterated Rating	Buy		High	i
1/15/2019	HC Wainwright	Reiterated Rating	Buy	$21.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
1/10/2019	Chardan Capital	Reiterated Rating	Neutral		Medium	i Rating by G. Amusa at Chardan Capital
1/8/2019	BTIG Research	Lower Price Target	Buy ➝ Positive	$23.00	Low	i
11/30/2018	HC Wainwright	Set Price Target	Buy	$25.00	Low	i Rating by Debjit Chattopadhyay at HC Wainwright
11/9/2018	HC Wainwright	Set Price Target	Buy	$25.00	Medium	i Rating by Debjit Chattopadhyay at HC Wainwright
11/8/2018	Robert W. Baird	Lower Price Target	Outperform ➝ Outperform	$31.00 ➝ $27.00	High	i
11/8/2018	Morgan Stanley	Set Price Target	Hold	$13.00	High	i Rating by Jeffrey Hung at Morgan Stanley
11/8/2018	Wedbush	Reiterated Rating	Outperform	$18.00 ➝ $28.00	High	i Rating by D. Nierengarten at Wedbush
9/10/2018	Morgan Stanley	Downgrade	Overweight ➝ Equal		High	i
9/10/2018	Morgan Stanley	Reiterated Rating	Overweight ➝ Equal Weight	$27.00	High	i
9/10/2018	BTIG Research	Reiterated Rating	Buy ➝ Buy	$32.00	Medium	i
8/8/2018	HC Wainwright	Set Price Target	Buy	$30.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
7/17/2018	Canaccord Genuity	Reiterated Rating	Buy	$31.00	High	i Rating by Sumant Kulkarni at Canaccord Genuity
7/17/2018	HC Wainwright	Set Price Target	Buy	$30.00	High	i Rating by Debjit Chattopadhyay at HC Wainwright
6/21/2018	Chardan Capital	Reiterated Rating	Hold	$30.00	High	i
6/7/2018	BTIG Research	Reiterated Rating	Buy	$32.00	Low	i
6/6/2018	Canaccord Genuity	Set Price Target	Buy	$35.00	Low	i Rating by Sumant Kulkarni at Canaccord Genuity
6/4/2018	HC Wainwright	Initiated Coverage	Buy	$30.00	High	i Rating by D. Chattopadhyay at HC Wainwright
5/29/2018	Canaccord Genuity	Set Price Target	Buy	$35.00	High	i Rating by Sumant Kulkarni at Canaccord Genuity
5/13/2018	BTIG Research	Reiterated Rating	Buy		High	i
5/11/2018	Wedbush	Upgrade	Neutral ➝ Outperform		High	i Rating by D. Nierengarten at Wedbush
5/10/2018	Canaccord Genuity	Set Price Target	Buy	$35.00	High	i Rating by Sumant Kulkarni at Canaccord Genuity
4/9/2018	Canaccord Genuity	Set Price Target	Buy	$35.00	High	i Rating by Sumant Kulkarni at Canaccord Genuity
3/14/2018	Canaccord Genuity	Set Price Target	Buy ➝ Buy	$36.00 ➝ $35.00	High	i Rating by Sumant Kulkarni at Canaccord Genuity
3/12/2018	Wedbush	Downgrade	Outperform ➝ Neutral	$29.00	High	i Rating by D. Nierengarten at Wedbush
3/12/2018	Piper Jaffray Companies	Reiterated Rating	Overweight ➝ Buy	$40.00	High	i Rating by Charles Duncan at Piper Jaffray Companies
3/11/2018	BTIG Research	Reiterated Rating	Buy	$32.00	High	i
2/21/2018	Wedbush	Boost Price Target	Outperform	$22.00 ➝ $29.00	High	i
2/21/2018	Morgan Stanley	Boost Price Target	Overweight ➝ Overweight	$36.00 ➝ $39.00	High	i
2/2/2018	Morgan Stanley	Initiated Coverage	Overweight ➝ Overweight		High	i
1/23/2018	Canaccord Genuity	Reiterated Rating	Buy	$26.00	Low	i Rating by Sumant Kulkarni at Canaccord Genuity
12/19/2017	BTIG Research	Initiated Coverage	Buy	$32.00	High	i
11/28/2017	Piper Jaffray Companies	Reiterated Rating	Overweight	$28.00	Medium	i Rating by Charles Duncan at Piper Jaffray Companies
11/20/2017	Wedbush	Reiterated Rating	Outperform	$22.00 ➝ $26.00	N/A	i
11/15/2017	Canaccord Genuity	Set Price Target	Buy	$26.00	N/A	i Rating by Sumant Kulkarni at Canaccord Genuity
10/31/2017	Chardan Capital	Reiterated Rating	Hold	$17.00	N/A	i Rating by Gbola Amusa at Chardan Capital
10/31/2017	Cowen	Reiterated Rating	Buy		N/A	i
10/31/2017	Wedbush	Reiterated Rating	Outperform ➝ Positive	$36.00 ➝ $31.00	N/A	i
10/30/2017	Robert W. Baird	Initiated Coverage	Outperform ➝ Outperform	$31.00	N/A	i
10/27/2017	Canaccord Genuity	Initiated Coverage	Buy ➝ Buy	$35.00	N/A	i
10/23/2017	Stifel Nicolaus	Reiterated Rating	Buy ➝ Buy	$20.00 ➝ $31.00	N/A	i
10/12/2017	Raymond James	Initiated Coverage	Outperform ➝ Outperform	$35.00	N/A	i
9/10/2017	Chardan Capital	Reiterated Rating	Hold		Medium	i Rating by Gbola Amusa at Chardan Capital
8/16/2017	Evercore ISI	Initiated Coverage	Outperform ➝ Outperform	$12.00	High	i
8/8/2017	Cowen	Reiterated Rating	Buy		Low	i
7/28/2017	Stifel Nicolaus	Initiated Coverage	Buy	$20.00	High	i
6/27/2017	Stifel Nicolaus	Reiterated Rating	Buy	$33.00	High	i
5/10/2017	Wedbush	Reiterated Rating	Outperform	$36.00	Medium	i
3/16/2017	Wedbush	Reiterated Rating	Outperform	$36.00	Medium	i
3/16/2017	Chardan Capital	Reiterated Rating	Neutral ➝ Neutral	$13.00	Low	i Rating by Gbola Amusa at Chardan Capital
3/1/2017	Nomura Instinet	Initiated Coverage	Buy ➝ Buy	$31.00	N/A	i
3/1/2017	Nomura Securities	Initiated Coverage	Buy		N/A	i
1/20/2017	Cowen	Reiterated Rating	Buy		N/A	i
1/20/2017	Wedbush	Reiterated Rating	Outperform	$36.00	N/A	i
12/8/2016	Cowen	Reiterated Rating	Buy		N/A	i Rating by Phil Nadeau at Cowen Inc
12/8/2016	Chardan Capital	Set Price Target	Positive ➝ Hold	$17.73 ➝ $11.00	N/A	i
12/8/2016	Wedbush	Reiterated Rating	Outperform	$36.00	N/A	i
11/13/2016	Piper Jaffray Companies	Reiterated Rating	Buy	$37.00	N/A	i Rating by joshua schimmer at Piper Jaffray Companies
11/10/2016	Wedbush	Reiterated Rating	Outperform	$36.00	N/A	i
11/10/2016	Cowen	Reiterated Rating	Buy		N/A	i Rating by Phil Nadeau at Cowen Inc
8/11/2016	Wedbush	Reiterated Rating	Outperform	$36.00	N/A	i
8/11/2016	Piper Jaffray Companies	Set Price Target	Buy	$37.00	N/A	i Rating by joshua schimmer at Piper Jaffray Companies
7/14/2016	Stifel Nicolaus	Initiated Coverage	Buy ➝ Buy	$33.00	N/A	i
6/22/2016	Piper Jaffray Companies	Reiterated Rating	Buy		N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
6/22/2016	Cowen	Reiterated Rating	Buy		N/A	i Rating by Phil Nadeau at Cowen Inc
6/22/2016	Wedbush	Reiterated Rating	Outperform	$36.00	N/A	i
5/20/2016	Wells Fargo & Company	Initiated Coverage	Outperform		N/A	i
5/12/2016	Piper Jaffray Companies	Reiterated Rating	Buy		N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
4/30/2016	Piper Jaffray Companies	Reiterated Rating	Buy		N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
3/20/2016	Wedbush	Reiterated Rating	Outperform	$36.00	N/A	i Rating by David Nierengarten at Wedbush
3/18/2016	Cowen	Reiterated Rating	Buy		N/A	i Rating by Phil Nadeau at Cowen Inc
3/18/2016	Piper Jaffray Companies	Reiterated Rating	Buy	$37.00	N/A	i Rating by Joshua Schimmer at Piper Jaffray Companies
1/25/2016	Chardan Capital	Upgrade	Sell ➝ Neutral	$20.00 ➝ $15.00	N/A	i Rating by Gbola Amusa MD CFA at Chardan Capital

(Data available from 1/20/2016 forward)

Voyager Therapeutics, Inc., a clinical-stage gene therapy company, focuses on the development of treatments for patients suffering from severe neurological diseases. The company's lead clinical candidate is the VY-AADC, which is in open-label Phase 1b clinical trial for the treatment of Parkinson's disease. Its preclinical programs comprise VY-SOD102 for the treatment of amyotrophic lateral sclerosis; VY-HTT01 for Huntington's disease; VY-FXN01 for Friedreich's ataxia; Tau program for the treatment of tauopathies, including Alzheimer's disease, progressive supranuclear palsy, and frontotemporal dementia; and alpha-synuclein program for synucleinopathies, Parkinson's disease, Lewy Body Dementia, and multiple system atrophy. The company has strategic collaboration agreements with the University of Massachusetts; and ClearPoint Neuro, Inc., as well as collaborations with Brammer Bio and Fujifilm Diosynth Biotechnologies to support the development of its gene therapy programs. It also has a collaboration and license agreement with Neurocrine Biosciences, Inc. for the research, development, and commercialization of adeno-associated virus-based gene therapy products. Voyager Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.

Today's Range

Now: $8.67

$8.52

$8.80

50 Day Range

MA: $8.12

$7.15

$9.28

52 Week Range

Now: $8.67

$6.26

$14.62

Volume

457,907 shs

Average Volume

416,760 shs

Market Capitalization

$324.83 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.8

Frequently Asked Questions

What sell-side analysts currently cover shares of Voyager Therapeutics?

The following equities research analysts have issued stock ratings on Voyager Therapeutics in the last year: Benchmark Co., BTIG Research, Canaccord Genuity, Cantor Fitzgerald, Chardan Capital, HC Wainwright, Morgan Stanley, Nomura, Nomura Securities, Oppenheimer Holdings Inc., Raymond James, Wedbush, Wells Fargo & Company, and Zacks Investment Research.

What is the current price target for Voyager Therapeutics?

13 Wall Street analysts have set twelve-month price targets for Voyager Therapeutics in the last year. Their average twelve-month price target is $15.38, suggesting a possible upside of 77.4%. Oppenheimer Holdings Inc. has the highest price target set, predicting VYGR will reach $26.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $10.00 for Voyager Therapeutics in the next year.

What is the current consensus analyst rating for Voyager Therapeutics?

Voyager Therapeutics currently has 6 hold ratings and 6 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe VYGR will outperform the market and that investors should add to their positions of Voyager Therapeutics.

What other companies compete with Voyager Therapeutics?

Other companies that are similar to Voyager Therapeutics include Coherus BioSciences, Aligos Therapeutics, Adverum Biotechnologies, Taysha Gene Therapies, Mesoblast, TCR2 Therapeutics, Sutro Biopharma, Black Diamond Therapeutics, Cortexyme, Compugen, Tarsus Pharmaceuticals, Athira Pharma, Gritstone Oncology, Prevail Therapeutics and Adaptimmune Therapeutics.

How do I contact Voyager Therapeutics' investor relations team?

Voyager Therapeutics' physical mailing address is 75 SIDNEY STREET, CAMBRIDGE MA, 02139. The company's listed phone number is 857-259-5340 and its investor relations email address is pcox@vygr.com. The official website for Voyager Therapeutics is www.voyagertherapeutics.com.

NASDAQ:VYGR - Voyager Therapeutics Stock Price Target and Predictions

Analyst Price Target for VYGR

Past Monthly Recommendations

Latest Recommendations

Today's Range

50 Day Range

52 Week Range

Volume

Average Volume

Market Capitalization

P/E Ratio

Dividend Yield

Beta

Frequently Asked Questions

What sell-side analysts currently cover shares of Voyager Therapeutics?

What is the current price target for Voyager Therapeutics?

What is the current consensus analyst rating for Voyager Therapeutics?

What other companies compete with Voyager Therapeutics?

How do I contact Voyager Therapeutics' investor relations team?